| Purpose:Comparing the expression of ER, PR, Her-2and Ki67before and after neo-adjuvant chemotherapy in breast cancer patents figured out whether there are changes in the express of ER, PR, Her-2and Ki67.Materials and methods:From July2009to September2010,92breast cancer patients treated with neo-adjuvant chemotherapy were identified and all of them were patients of Surgical Oncology Department of Sir Run Run Shaw Hospital, Zhejiang University. All the patients were got adequate tissue sample in the way of core needle biopsy (CNB), three days before any treatment. The expression pattern of ER, PR, Her-2and Ki67was analyzed in primary core needle biopsy and surgical specimen in the same way of immunohistochemical examination.Results:In this study, we found that23.9%of the cases appear to change in the express of ER before and after neo-adjuvant chemotherapy, using the Wilcoxon rank sum test method, with a significant difference (P<0.05);31.5%of the cases appeared to change in the express of PR;13.0%of the cases appeared to change in the express of Her-2;37.1%of the cases appeared to change in the express of Ki67. The express differences of PR, Her-2of Ki67before and after neo-adjuvant were not statistically significant (P>0.05).Conclusion:The express ER, PR, Her-2and Ki67changed in some cases after neo-adjuvant chemotherapy, but in this case, only the express of ER statistically significant changed before and after neo-adjuvant chemotherapy. The express of PR, Her-2and Ki67had no significant statistical significance. |
PDF Full Text Request